Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2015 Aug 5;8(2):339-44.
doi: 10.1159/000438785. eCollection 2015 May-Aug.

Metastatic Prostatic Ductal Adenocarcinoma Successfully Treated with Docetaxel Chemotherapy: A Case Report

Ryo Fujiwara  1 , Susumu Kageyama  1 , Keiji Tomita  1 , Eiki Hanada  1 , Teruhiko Tsuru  1 , Tetsuya Yoshida  1 , Mitsuhiro Narita  1 , Takahiro Isono  2 , Akihiro Kawauchi  1
Affiliations
Case Reports

Metastatic Prostatic Ductal Adenocarcinoma Successfully Treated with Docetaxel Chemotherapy: A Case Report

Ryo Fujiwara et al. Case Rep Oncol. .

Abstract

A 68-year-old man presented with gross hematuria. A papillary urethral tumor adjacent to the verumontanum was found by cystourethroscopy. Serum prostate-specific antigen (PSA) was 3.246 ng/ml. A transurethral biopsy specimen was most suggestive of a primary urothelial carcinoma of the prostate, for which a radical cystoprostatectomy was performed. The final pathology was prostatic ductal adenocarcinoma with very focal acinar features (Gleason score 5 %plus; 4 = 9, pT3bN0M0). Local recurrence and pelvic bone metastases developed 17 months later, and his PSA rose to 10.806 ng/ml. He was treated with combined androgen blockade and radiation. Two years later, the lesion showed progressive growth. Treatment followed with docetaxel (70 mg/m(2) every 3 weeks) and prednisolone 5 mg twice daily. After 10 cycles of chemotherapy, all lesions disappeared and PSA decreased to <0.005 ng/ml. Three years after chemotherapy, he maintains a complete response without any additional treatments. Docetaxel chemotherapy can be an effective treatment for patients with recurrent prostatic ductal adenocarcinoma.

Keywords: Chemotherapy; Docetaxel; Prostatic ductal adenocarcinoma.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Contrast-enhanced MRI. The lesion was shown as a low-intensity area with circular enhancement near the verumontanum (arrow).
Fig. 2
Fig. 2
Histopathology of a ductal adenocarcinoma: comedonecrosis and cribriform pattern seen in the specimen. HE stain. ×400.
Fig. 3
Fig. 3
Longitudinal PSA values during treatment. LH-RH = Luteinizing hormone-releasing hormone.
See this image and copyright information in PMC

References

    1. Orihuela E, Green JM. Ductal prostate cancer: contemporary management and outcomes. Urol Oncol. 2008;26:368–371. - PubMed
    1. Yang XJ, Cheng L, Helpap B, Samaratunga H. Ductal adenocarcinoma. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editor. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Urinary System and Male Genital Organs. ed 3. Vol. 7. Lyon: IARC; 2004. pp. 199–201.
    1. Melicow MM, Pachter MR. Endometrial carcinoma of prostatic utricle (uterus masculinus) Cancer. 1967;20:1715–1722. - PubMed
    1. Bock BJ, Bostwick DG. Does prostatic ductal adenocarcinoma exist? Am J Surg Pathol. 1999;23:781–785. - PubMed
    1. Iğdem S, Spiegel DY, Efstathiou J, Miller RC, Poortmans PM, Koca S, Kiliç-Unsal D, Okkan S, Zietman A. Prostatic duct adenocarcinoma: clinical characteristics, treatment options, and outcomes – a rare cancer network study. Onkologie. 2010;33:169–173. - PubMed

Publication types